Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County

被引:49
作者
Duan, Lei [1 ,2 ]
Wu, Anna H. [2 ]
Sullivan-Halley, Jane [2 ]
Bernstein, Leslie [2 ]
机构
[1] Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Los Angeles, CA USA
[2] Univ So Calif, Dept Prevent Med, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA
关键词
D O I
10.1158/1055-9965.EPI-07-0664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Nonsteroidal anti-inflammatory drug (NSAID) use has been associated with a reduced risk of colon cancer; further epidemiologic data appear consistent for stomach and esophageal adenocarcinomas. Yet, data on potential confounding effects by upper gastrointestinal tract (UGI) disorders on adenocarcinomas of the UGI are limited. Methods: This study recruited newly diagnosed patients with esophageal adenocarcinoma (n = 220), gastric cardia adenocarcinoma (n = 277), or distal gastric adenocarcinoma (n = 441) as well as 1,356 control subjects in Los Angeles County. Unconditional multivariable logistic regression analyses were done to evaluate the association between regular NSAID use, at least two pills per week for 1 month, and these cancers. Results: Duration of regular use of aspirin and nonaspirin NSAIDs was associated with reduced relative odds of distal gastric adenocarcinoma [> 5 years use versus no regular use: odds ratio (OR), 0.61; 95% confidence interval, 0.40-0.92; P-trend = 0.0091 and esophageal adenocarcinoma (OR, 0.60; 95% confidence interval, 0.38-0.95; P-tnend = 0.04) in multivariable models that included history of UGI disorders and other potential confounding factors. Daily regular use was also associated with statistically significant reduced ORs of these two tumor types. No significant heterogeneity in risk estimates was noted after stratification by history of UGI disorders for any of the sites studied. However, irregular users of NSAIDs also had reduced risk of these cancers when compared with nonusers. Conclusions: Results from this study support an inverse association between regular NSAID use and risk of esophageal and distal gastric adenocarcinomas in individuals with and without a history of UGI disorders with long duration and daily use, providing the greatest risk reduction. Reduced risk in irregular users suggests that factors other than an effect on cyclooxygenase may also be important.
引用
收藏
页码:126 / 134
页数:9
相关论文
共 44 条
[1]   Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells [J].
Abdalla, SI ;
Sanderson, IR ;
Fitzgerald, RC .
CARCINOGENESIS, 2005, 26 (09) :1627-1633
[2]   Aspirin and risk for gastric cancer:: a population-based case-control study in Sweden [J].
Akre, K ;
Ekström, AM ;
Signorello, LB ;
Hansson, LE ;
Nyrén, O .
BRITISH JOURNAL OF CANCER, 2001, 84 (07) :965-968
[3]   Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence [J].
Anderson, Lesley A. ;
Johnston, Brian T. ;
Watson, R. G. Peter ;
Murphy, Seamus J. ;
Ferguson, Heather R. ;
Comber, Harry ;
McGuigan, Jim ;
Reynolds, John V. ;
Murray, Liam J. .
CANCER RESEARCH, 2006, 66 (09) :4975-4982
[4]  
Baron JA, 2003, PROG EXP TUMOR RES, V37, P1
[5]   Nonsteroidal anti-inflammatory drugs and cancer prevention [J].
Baron, JA ;
Sandler, RS .
ANNUAL REVIEW OF MEDICINE, 2000, 51 :511-523
[6]   Aspirin and cancer risk: an update to 2001 [J].
Bosetti, C ;
Gallus, S ;
La Vecchia, C .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2002, 11 (06) :535-542
[7]  
Buttar NS, 2002, JNCI-J NATL CANCER I, V94, P422
[8]   Nonsteroidal anti-inflammatory drugs for treatment of advanced gastric cancer: cyclooxygenase-2 is involved in hepatocyte growth factor mediated tumor development and progression [J].
Chen, JH ;
Liu, TY ;
Wu, CW ;
Chi, CW .
MEDICAL HYPOTHESES, 2001, 57 (04) :503-505
[9]  
Coogan PF, 2000, CANCER EPIDEM BIOMAR, V9, P119
[10]   Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis [J].
Corley, DA ;
Kerlikowske, K ;
Verma, R ;
Buffler, P .
GASTROENTEROLOGY, 2003, 124 (01) :47-56